China Hypotheticals

The Anti-Corruption Crackdown in China and Nightmare Scenarios: How Companies Are Now Approaching High Stakes, Intensifying Legal and Compliance Risks

May 9, 2024 11:15am

Adam Yoffie
Executive Director, Head of C&E Investigations and Integrity Line
Bristol Myers Squibb
Former Trial Attorney, Criminal Division U.S. Department of Justice

Lamia Matta
Global Head of Investigations
3M Healthcare

Susanne M. Hanchar
Associate Vice President – Global Ethics and Compliance, Anti-Corruption & Investigations
Eli Lilly and Company

Yuet Tham
Sidley Austin (Hong Kong)

Building upon the pre-conference workshop, this interactive, practical session delves select, highly complex issues affecting the life sciences and healthcare sectors in China. Benefit from enhanced benchmarking by using our anonymous polling systems!

  • The anti-corruption crackdown in China: How might this campaign negatively impact HCPs and advances in healthcare?
  • Critical regional compliance implications for life science companies such as pricing, reimbursement, and market access issues
  • Navigating WeChat and WhatsApp communication landmines: Document sharing, data retention
  • Data protection and blocking statutes: Balancing these laws with DOJ and SEC expectations for FCPA compliance
  • What go-to-market considerations are most important in crafting a winning strategy in response to rapid health reforms taking place in China?